Clinical Research Directory
Browse clinical research sites, groups, and studies.
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Sponsor: Institut Paoli-Calmettes
Summary
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.
Official title: Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
135
Start Date
2018-01-29
Completion Date
2025-06-25
Last Updated
2026-04-21
Healthy Volunteers
No
Conditions
Interventions
Blood sample collection
Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
Biopsy collection
Optional biopsy collection at baseline and progression
Locations (1)
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France